Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zelira Therapeutics ( (AU:ZLD) ) has provided an update.
Zelira Therapeutics’ 2025 Annual General Meeting highlighted the company’s focus on validating its operational scale. The announcement underscores Zelira’s strategic intentions and future plans, acknowledging the inherent risks and uncertainties in achieving these objectives. The company’s efforts to expand its operational capabilities are crucial for its positioning in the cannabinoid therapeutics industry, with potential implications for stakeholders as it navigates market challenges.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics is a company operating in the pharmaceutical industry, focusing on the development and commercialization of cannabinoid-based medicines. The company is listed on the Australian Securities Exchange (ASX: ZLD) and the OTCQB (ZLDAF) and is committed to advancing its operational scale in the cannabinoid therapeutics market.
Average Trading Volume: 5,865
Technical Sentiment Signal: Sell
Current Market Cap: A$4.05M
Learn more about ZLD stock on TipRanks’ Stock Analysis page.